{"ref-id":"L4626","title":"Aids info document","url":"https://aidsinfo.nih.gov/drugs/487/peginterferon-alfa-2b--hcv/136/professional","parent_key":"BE0002793"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0002362"}
{"ref-id":"L3734","title":"Neoral (Cyclosporine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s027,050716s028lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0002638"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0002638"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0002363"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0002433"}
{"ref-id":"L7544","title":"FDA label, fluvoxamine","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L2905","title":"Drug Interactions & Labeling - FDA","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2","parent_key":"BE0002638"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0004866"}
{"ref-id":"L2905","title":"Drug Interactions & Labeling - FDA","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2","parent_key":"BE0004866"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0002793"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0003536"}
{"ref-id":"L4784","title":"Benzodiazepine metabolism and pharmacokinetic","url":"http://paindr.com/wp-content/uploads/2015/10/Revised-BZD_-9-30.pdf","parent_key":"BE0002638"}
{"ref-id":"L14177","title":"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L14177","title":"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L14177","title":"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L14177","title":"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L14177","title":"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L4582","title":"Betaxolol, Pediatric Care Solutions","url":"https://pediatriccare.solutions.aap.org/drug.aspx?gbosid=171921","parent_key":"BE0002433"}
{"ref-id":"L6505","title":"Fluconazole, Medsafe NZ data sheet","url":"https://www.medsafe.govt.nz/profs/Datasheet/f/fluconazolecapmylan.pdf","parent_key":"BE0002638"}
{"ref-id":"L6505","title":"Fluconazole, Medsafe NZ data sheet","url":"https://www.medsafe.govt.nz/profs/Datasheet/f/fluconazolecapmylan.pdf","parent_key":"BE0002793"}
{"ref-id":"L6505","title":"Fluconazole, Medsafe NZ data sheet","url":"https://www.medsafe.govt.nz/profs/Datasheet/f/fluconazolecapmylan.pdf","parent_key":"BE0003536"}
{"ref-id":"L7261","title":"FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0003612"}
{"ref-id":"L7261","title":"FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf","parent_key":"BE0003612"}
{"ref-id":"L7261","title":"FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L9851","title":"Caffeine citrate injection FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20793s1lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L2905","title":"Drug Interactions & Labeling - FDA","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2","parent_key":"BE0003536"}
{"ref-id":"L2924","title":"Ticlopidine Hydrochloride - Drug Summary - PDR","url":"http://www.pdr.net/drug-summary/Ticlopidine-Hydrochloride-ticlopidine-hydrochloride-3029","parent_key":"BE0003536"}
{"ref-id":"L2924","title":"Ticlopidine Hydrochloride - Drug Summary - PDR","url":"http://www.pdr.net/drug-summary/Ticlopidine-Hydrochloride-ticlopidine-hydrochloride-3029","parent_key":"BE0002433"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0003549"}
{"ref-id":"L2924","title":"Ticlopidine Hydrochloride - Drug Summary - PDR","url":"http://www.pdr.net/drug-summary/Ticlopidine-Hydrochloride-ticlopidine-hydrochloride-3029","parent_key":"BE0003549"}
{"ref-id":"L8126","title":"Citalopram FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020822s042,021046s019lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L8129","title":"Eletriptan FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021016s018lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8132","title":"Nelfinavir FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021503s006lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L2906","title":"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table2-2","parent_key":"BE0002638"}
{"ref-id":"L2915","title":"TABLETS MEVACOR\u001a (LOVASTATIN) FDA LABEL","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019643s085lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L5296","title":"Public presentations","url":"https://www.lipid.org/sites/default/files/f-_wiggins_final.pdf","parent_key":"BE0003677"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0003533"}
{"ref-id":"L4349","title":"Viramune (Nevirapine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20636s025,20933s014lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L2904","title":"Indiana University - Department of Medicine Clinical Pharmacology","url":"http://medicine.iupui.edu/clinpharm/ddis/main-table","parent_key":"BE0002638"}
{"ref-id":"L2918","title":"Lexicomp database","url":"http://www.wolterskluwercdi.com/","parent_key":"BE0002638"}
{"ref-id":"L4349","title":"Viramune (Nevirapine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20636s025,20933s014lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L2919","title":"Nevirapine","url":"https://aidsinfo.nih.gov/drugs/116/nevirapine/17/professional","parent_key":"BE0002433"}
{"ref-id":"L5473","title":"Australian Assessment Report","url":"https://www.tga.gov.au/sites/default/files/auspar-ranolazine-180220.pdf","parent_key":"BE0002638"}
{"ref-id":"L3580","title":"Ranolazine FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021526s007lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L3580","title":"Ranolazine FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021526s007lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0002793"}
{"ref-id":"L2903","title":"Cytochrome P450 2C19 by Straight Healthcare","url":"https://www.straighthealthcare.com/cytochrome-p450-2c19.html","parent_key":"BE0003536"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0003536"}
{"ref-id":"L3852","title":"NCI/NIH","url":"https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47598&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null","parent_key":"BE0002638"}
{"ref-id":"L14153","title":"FDA Approved Drug Products: Agrylin (anagrelide) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020333s026lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L5530","title":"Researchgate publications","url":"https://www.researchgate.net/publication/257614687_Chemical_stability-indicating_HPLC_study_of_fixed-dosage_combination_containing_metoprolol_tartrate_and_hydrochlorothiazide","parent_key":"BE0002638"}
{"ref-id":"L2914","title":"Get to Know an Enzyme: CYP3A4 Substrates","url":"https://www.pharmacytimes.com/publications/issue/2008/2008-09/2008-09-8687","parent_key":"BE0002638"}
{"ref-id":"L10256","title":"Supercyp table","url":"http://bioinformatics.charite.de/supercyp/index.php?site=get_drug_interaction","parent_key":"BE0002638"}
{"ref-id":"L10544","title":"FDA label, topiramate","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020505s057_020844s048lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L3791","title":"Topamax (Topiramate) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020844s041lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L3810","title":"Monograph","url":"https://pdf.hres.ca/dpd_pm/00039966.PDF","parent_key":"BE0002638"}
{"ref-id":"L3811","title":"Cyclocort monograph","url":"https://ca.gsk.com/media/1187406/cyclocort.pdf","parent_key":"BE0002638"}
{"ref-id":"L8330","title":"STRATTERA (atomoxetine HCl) - FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021411s018lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L5695","title":"PMC","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683610/","parent_key":"BE0002638"}
{"ref-id":"L8312","title":"Prescriber's digital reference, Marcaine with Epinephrine-bipuvacaine-hydrochloride","url":"https://www.pdr.net/drug-summary/Marcaine-Marcaine-with-Epinephrine-bupivacaine-hydrochloride----bupivacaine-hydrochloride-epinephrine-1700","parent_key":"BE0002363"}
{"ref-id":"L2902","title":"CYP2A6 cytochrome P450 family 2 subfamily A member 6 [ Homo sapiens (human) ]","url":"https://www.ncbi.nlm.nih.gov/gene/1548","parent_key":"BE0003336"}
{"ref-id":"L8288","title":"IRESSA (gefitinib) tablets for oral use - FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L171","title":"Link","url":"https://www.pharmgkb.org/pathway/PA152325160","parent_key":"BE0003543"}
{"ref-id":"L171","title":"Link","url":"https://www.pharmgkb.org/pathway/PA152325160","parent_key":"BE0002793"}
{"ref-id":"L171","title":"Link","url":"https://www.pharmgkb.org/pathway/PA152325160","parent_key":"BE0003536"}
{"ref-id":"L4640","title":"Up to Date: Floxuridine","url":"http://uptodatefree.com/topic/floxuridine-drug-information","parent_key":"BE0002793"}
{"ref-id":"L8174","title":"Opioid Metabolism and Effects of Cytochrome P450","url":"https://watermark.silverchair.com/10-suppl_1-S20.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAm4wggJqBgkqhkiG9w0BBwagggJbMIICVwIBADCCAlAGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM3P717upZvwRrCHzhAgEQgIICIUV8V0_1BDbWmW8s1ojPqcCrNNrisap3Ubc8wwOpzvvTTRTYkF50Ylq4DZjirW_ygB8kbr15zzBNHpZSnDhjx993jMJdXHl2mAy9QwjP3CXgbzG_909Xwn8dwNOVokYT3zkIqP4d-TQHQEcI7BntlSZeaYLs3YoHUPBUe7gWY8GS8CeU3BG9nzAltOjHHd_eeRqm8VmmTskQ8-nc58dItL7lWji20_W3rtDduM959MGYJgcqKs0kV1Dc_C44lzmbHGrZv3XinDVMEhddUlDeR13d7tuarwyK_bVa5x9NrJN88fMCAvmyCSYHv6TJadBITpGXAnmlrEb-ms471oTfS4oAPlDZtAXZebW8tWlIyuIdAHbr6bbA4fYDK3-j0oVa8oITyKlpJn9bl_uLpDplUhCPHnujLBJUXETzIijxE3InxVhYimHe1lj-8aoWEZPlP6CjnxcTpLGsPK5zWJaBwwH6hHkNH3ZXHVueE42tkx9zYqOWA6kKFWgYg2G2DpMAOcfdVoODRsOWT2YebJdRWNlI5erBuq_Bygal9Lf6I9mOtS52G4He-WHPuINB3i4b4uCFIVH8lQCMqc3Iv9BC20vzOo4I-koErjTivfKgGmJsCHZ1lLtqt4Ajpj0_bzfjl6VN2jEE3IxeBKTdTl3mRHpBVx6DhBhOMHPtDgbVnfekWHd4KK56DWTUcETZBNrOVHB-e0aiudCdyFtWtsM_GetJ","parent_key":"BE0003549"}
{"ref-id":"L8327","title":"SYMBYAX\u001a (olanzapine and fluoxetine HCl capsules) - FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21520_symbyax_lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L8177","title":"Co-Administration of the CYP3A4 Inhibitor Diltiazem Counteracts Mitotane-Induced Clearance of Glucocorticoids and Antihypertensives in a Patient with Adrenocortical Carcinoma","url":"https://journals.aace.com/doi/pdf/10.4158/EP15686.CR","parent_key":"BE0002638"}
{"ref-id":"L2905","title":"Drug Interactions & Labeling - FDA","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2","parent_key":"BE0002362"}
{"ref-id":"L2905","title":"Drug Interactions & Labeling - FDA","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2","parent_key":"BE0003612"}
{"ref-id":"L9767","title":"Clobazam FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202067s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8291","title":"Clozapine Therapy and CYP2D6, CYP1A2, and CYP3A4 Genotypes","url":"https://www.ncbi.nlm.nih.gov/books/NBK367795/","parent_key":"BE0002363"}
{"ref-id":"L8291","title":"Clozapine Therapy and CYP2D6, CYP1A2, and CYP3A4 Genotypes","url":"https://www.ncbi.nlm.nih.gov/books/NBK367795/","parent_key":"BE0002638"}
{"ref-id":"L7760","title":"Levonorgestrel FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021998lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L6727","title":"Timolol maleate tablet","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57c62928-63d8-4505-9b9e-c085a3a12c95","parent_key":"BE0002363"}
{"ref-id":"L2906","title":"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table2-2","parent_key":"BE0002433"}
{"ref-id":"L5662","title":"CYP3A5 cytochrome P450 family 3 subfamily A member 5 [ Homo sapiens (human) ]","url":"https://www.ncbi.nlm.nih.gov/gene/1577","parent_key":"BE0002362"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0002887"}
{"ref-id":"L10190","title":"Griseofulvin drug summary","url":"https://www.pdr.net/drug-summary/Gris-PEG-griseofulvin-934","parent_key":"BE0002638"}
{"ref-id":"L6769","title":"Eszopiclone FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4265","title":"FDA Approved Drug Products: XANAX (Alprazolam) tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018276s052lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L3994","title":"Cleveland clinic","url":"http://portals.clevelandclinic.org/portals/66/PDF/techbriefs/TB_GeneticTestOfCytochromeP4502C19ForDrugMetabolism.pdf","parent_key":"BE0003536"}
{"ref-id":"L3863","title":"Academic disertation","url":"https://pdfs.semanticscholar.org/dc99/4682bd504ab29f1c7075b9d769eb4ac4a9ce.pdf","parent_key":"BE0002638"}
{"ref-id":"L2905","title":"Drug Interactions & Labeling - FDA","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2","parent_key":"BE0002433"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0002433"}
{"ref-id":"L7108","title":"QUALAQUIN\u001a quinine sulfate - FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021799s008lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L4118","title":"PDR INTERACTIONS QUININE","url":"http://www.pdr.net/drug-summary/Qualaquin-quinine-sulfate-828","parent_key":"BE0003536"}
{"ref-id":"L7108","title":"QUALAQUIN\u001a quinine sulfate - FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021799s008lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L3607","title":"FDA Approved Drug Products: Qualaquin ((quinine sulfate) Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021799s023lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L6301","title":"Singulair (montelukast sodium) US FDA Label 2019","url":"https://www.merck.com/product/usa/pi_circulars/s/singulair/singulair_pi.pdf","parent_key":"BE0002887"}
{"ref-id":"L7874","title":"Fluoxetine Metabolism Pathway","url":"http://smpdb.ca/view/SMP0000646","parent_key":"BE0003536"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0002363"}
{"ref-id":"L10244","title":"Fluoxetine FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4558","title":"PharmGKB: Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics Overview","url":"https://www.pharmgkb.org/pathway/PA165859361","parent_key":"BE0002638"}
{"ref-id":"L7529","title":"Pharm KGB Very Important Pharmacogene: CYP2D6","url":"https://www.pharmgkb.org/vip/PA166170264","parent_key":"BE0002363"}
{"ref-id":"L8210","title":"NORVIR (ritonavir) - FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209512lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0003549"}
{"ref-id":"L3326","title":"Interactions","url":"https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf","parent_key":"BE0009758"}
{"ref-id":"L81","title":"Source","url":"http://www.currentseparations.com/issues/20-3/20-3d.pdf","parent_key":"BE0002363"}
{"ref-id":"L14363","title":"FDA Approved Drug Products: Neudexta Dextromethorphan Hydrobromide and Quinidine Sulfate Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021879s014lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L9218","title":"FDA Approved Drugs Products: Albendazole Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf","parent_key":"BE0003543"}
{"ref-id":"L9218","title":"FDA Approved Drugs Products: Albendazole Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L8318","title":"Caspofungin EMA label","url":"https://www.ema.europa.eu/en/documents/product-information/caspofungin-accord-epar-product-information_en.pdf","parent_key":"BE0002638"}
{"ref-id":"L4506","title":"LERCANIDIPINE - Australian Prescribing Information","url":"http://www.medicines.org.au/files/txplerca.pdf","parent_key":"BE0002638"}
{"ref-id":"L164","title":"Source","url":"http://herkules.oulu.fi/isbn9514259009/html/index.html","parent_key":"BE0003549"}
{"ref-id":"L4536","title":"NCBI Cytochrome P450 CYP2C8 Profile","url":"https://www.ncbi.nlm.nih.gov/gene/1558","parent_key":"BE0002887"}
{"ref-id":"L8438","title":"VIOXX\u001a (rofecoxib tablets and oral suspension) - FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L7532","title":"The Inhibitory Effect of Amoxapine on Cytochrome P450 Enzyme Activity in Human Liver Microsomes","url":"https://www.jstage.jst.go.jp/article/sujms1989/16/4/16_4_329/_article/-char/en","parent_key":"BE0002363"}
{"ref-id":"L9404","title":"Lamictal FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020241s060,020764s053,022251s024lbl.pdf","parent_key":"BE0009758"}
{"ref-id":"L9680","title":"Health Canada Product Monograph: Hydroxyzine HCl oral capsules","url":"https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf","parent_key":"BE0002638"}
{"ref-id":"L9680","title":"Health Canada Product Monograph: Hydroxyzine HCl oral capsules","url":"https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf","parent_key":"BE0002362"}
{"ref-id":"L9764","title":"FDA table of interactions","url":"https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers","parent_key":"BE0002638"}
{"ref-id":"L9758","title":"FDA interactions table","url":"https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#cypEnzymes","parent_key":"BE0002638"}
{"ref-id":"L1334","title":"Tegretol FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016608s101,018281s048lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4596","title":"CYP table","url":"https://drug-interactions.medicine.iu.edu/Clinical-Table.aspx","parent_key":"BE0002433"}
{"ref-id":"L2904","title":"Indiana University - Department of Medicine Clinical Pharmacology","url":"http://medicine.iupui.edu/clinpharm/ddis/main-table","parent_key":"BE0003536"}
{"ref-id":"L7195","title":"Pharm KGB, carbamazepine pathway, pharmacokinetics","url":"https://www.pharmgkb.org/pathway/PA165817070","parent_key":"BE0003549"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0002362"}
{"ref-id":"L7195","title":"Pharm KGB, carbamazepine pathway, pharmacokinetics","url":"https://www.pharmgkb.org/pathway/PA165817070","parent_key":"BE0003679"}
{"ref-id":"L3868","title":"FDA reports","url":"https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM421134.pdf","parent_key":"BE0002887"}
{"ref-id":"L7294","title":"Cardura XL label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021269s011lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L7294","title":"Cardura XL label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021269s011lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L4870","title":"Dailymed","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed04255-7d9c-464c-bfa6-c355755862d8","parent_key":"BE0002638"}
{"ref-id":"L7294","title":"Cardura XL label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021269s011lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L7297","title":"Cardura monograph","url":"https://www.pfizer.ca/sites/g/files/g10050796/f/201710/CARDURA_PM_Eng_201486_4Apr2017.pdf","parent_key":"BE0002638"}
{"ref-id":"L7297","title":"Cardura monograph","url":"https://www.pfizer.ca/sites/g/files/g10050796/f/201710/CARDURA_PM_Eng_201486_4Apr2017.pdf","parent_key":"BE0002793"}
{"ref-id":"L10235","title":"Abbvie: Venetoclax","url":"https://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/VENCLEXTA_PM_EN.pdf","parent_key":"BE0002638"}
{"ref-id":"L7219","title":"Bisoprolol monograph","url":"https://www.sandoz.ca/sites/www.sandoz.ca/files/Bisoprolol_TAB_Monograph.pdf","parent_key":"BE0002638"}
{"ref-id":"L3517","title":"Mycobutin (Rifabutin) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050689s016lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4397","title":"GLEEVEC (imatinib mesylate) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8342","title":"Fluphenazine - StatPearls - NCBI Bookshelf","url":"https://www.ncbi.nlm.nih.gov/books/NBK459194/","parent_key":"BE0003533"}
{"ref-id":"L81","title":"Source","url":"http://www.currentseparations.com/issues/20-3/20-3d.pdf","parent_key":"BE0002638"}
{"ref-id":"L9764","title":"FDA table of interactions","url":"https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers","parent_key":"BE0002362"}
{"ref-id":"L80","title":"Website","url":"http://www.ihop-net.org/UniPub/iHOP/","parent_key":"BE0002638"}
{"ref-id":"L3484","title":"Trazodone","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L3837","title":"CRDD","url":"http://crdd.osdd.net/raghava/metapred/SupplemantryData.doc","parent_key":"BE0002638"}
{"ref-id":"L8099","title":"niLUTAmide - Cancer Care Ontario","url":"https://www.cancercareontario.ca/sites/ccocancercare/files/nilutamide.pdf","parent_key":"BE0003536"}
{"ref-id":"L8102","title":"Nilutamide Monograph - BC Cancer","url":"http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Nilutamide_monograph_1Aug07.pdf","parent_key":"BE0003536"}
{"ref-id":"L4066","title":"Health Canada Approved Drug Products: Manerix (Moclobemide) tablets","url":"https://pdf.hres.ca/dpd_pm/00032713.PDF","parent_key":"BE0002363"}
{"ref-id":"L8105","title":"Thioridazine Therapy and CYP2D6 Genotypes","url":"https://www.ncbi.nlm.nih.gov/books/NBK424018/","parent_key":"BE0002363"}
{"ref-id":"L3702","title":"Cafergot (Ergotamine tartrate and Caffeine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/9000s22s23lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L3766","title":"Delavirdine FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L13919","title":"FDA Approved Drug Products: Apomorphine Subcutaneous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L13919","title":"FDA Approved Drug Products: Apomorphine Subcutaneous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L13919","title":"FDA Approved Drug Products: Apomorphine Subcutaneous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L13919","title":"FDA Approved Drug Products: Apomorphine Subcutaneous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L13919","title":"FDA Approved Drug Products: Apomorphine Subcutaneous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf","parent_key":"BE0009758"}
{"ref-id":"L165","title":"Source","url":"http://www.healthscout.com/rxdetail/68/110/8/main.html","parent_key":"BE0002363"}
{"ref-id":"L8108","title":"Esomeprazole Therapy and CYP2C19 Genotype","url":"https://www.ncbi.nlm.nih.gov/books/NBK100896/","parent_key":"BE0003536"}
{"ref-id":"L4606","title":"FDA Approved Drug Products: ZYFLO CR (zileuton) extended-release tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022052s005lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L9758","title":"FDA interactions table","url":"https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#cypEnzymes","parent_key":"BE0002362"}
{"ref-id":"L8279","title":"Clopidogrel Therapy and CYP2C19 Genotype","url":"https://www.ncbi.nlm.nih.gov/books/NBK84114/","parent_key":"BE0003536"}
{"ref-id":"L8627","title":"FDA Approved Drugs: Oxcarbazepine","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021014s043lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L8630","title":"DPD Approved Drugs: Oxcarbazepine","url":"https://pdf.hres.ca/dpd_pm/00048247.PDF","parent_key":"BE0003536"}
{"ref-id":"L8633","title":"MedSafe NZ: Oxcarbazepine","url":"https://www.medsafe.govt.nz/profs/Datasheet/t/Trileptaltab.pdf","parent_key":"BE0003536"}
{"ref-id":"L8627","title":"FDA Approved Drugs: Oxcarbazepine","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021014s043lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8630","title":"DPD Approved Drugs: Oxcarbazepine","url":"https://pdf.hres.ca/dpd_pm/00048247.PDF","parent_key":"BE0002638"}
{"ref-id":"L8633","title":"MedSafe NZ: Oxcarbazepine","url":"https://www.medsafe.govt.nz/profs/Datasheet/t/Trileptaltab.pdf","parent_key":"BE0002638"}
{"ref-id":"L3971","title":"Trileptal (Oxcarbazepine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021014s036lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8627","title":"FDA Approved Drugs: Oxcarbazepine","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021014s043lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L8630","title":"DPD Approved Drugs: Oxcarbazepine","url":"https://pdf.hres.ca/dpd_pm/00048247.PDF","parent_key":"BE0002362"}
{"ref-id":"L8633","title":"MedSafe NZ: Oxcarbazepine","url":"https://www.medsafe.govt.nz/profs/Datasheet/t/Trileptaltab.pdf","parent_key":"BE0002362"}
{"ref-id":"L11485","title":"FDA Approved Products: Estrace (Estradiol) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L162","title":"Flockhart Table of Drug Interactions","url":"https://drug-interactions.medicine.iu.edu/Main-Table.aspx","parent_key":"BE0003543"}
{"ref-id":"L4624","title":"primidone - Drug Summary","url":"https://www.pdr.net/drug-summary/Mysoline-primidone-775","parent_key":"BE0002793"}
{"ref-id":"L11398","title":"FDA approved products: Mobic (meloxicam) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020938s024s025,021530s014s015lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L11398","title":"FDA approved products: Mobic (meloxicam) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020938s024s025,021530s014s015lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8006","title":"Cancer.gov CTEP document","url":"https://ctep.cancer.gov/protocoldevelopment/docs/cyp2c89.doc","parent_key":"BE0002887"}
{"ref-id":"L3826","title":"Gene labs","url":"http://genelabs.com/drugsdb/details/ethynodiol-diacetate/","parent_key":"BE0002638"}
{"ref-id":"L8282","title":"Diazepam Therapy and CYP2C19 Genotype","url":"https://www.ncbi.nlm.nih.gov/books/NBK379740/","parent_key":"BE0002362"}
{"ref-id":"L3576","title":"Mifeprex (Mifepristone) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4651","title":"PDR","url":"https://www.pdr.net/drug-summary/Korlym-mifepristone-2928.2022","parent_key":"BE0002793"}
{"ref-id":"L13802","title":"FDA Approved Drug Products: Lamprene (clofazimine) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L13802","title":"FDA Approved Drug Products: Lamprene (clofazimine) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L13802","title":"FDA Approved Drug Products: Lamprene (clofazimine) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L3841","title":"NCI/NIH","url":"https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47537&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null","parent_key":"BE0002638"}
{"ref-id":"L8009","title":"BC Cancer website","url":"http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Dacarbazine_monograph_1June2013_formatted.pdf","parent_key":"BE0003543"}
{"ref-id":"L9065","title":"FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L9065","title":"FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L9065","title":"FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L9065","title":"FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L9065","title":"FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L9065","title":"FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L8012","title":"Bayer monograph, Levitra","url":"https://www.bayer.ca/omr/online/levitra-pm-en.pdf","parent_key":"BE0002362"}
{"ref-id":"L6991","title":"Ranitidine drug summary","url":"https://www.pdr.net/drug-summary/Ranitidine-Hydrochloride-Capsules-and-Tablets-ranitidine-hydrochloride-2965","parent_key":"BE0002638"}
{"ref-id":"L3850","title":"NCI/NIH","url":"https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C72818&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null","parent_key":"BE0002638"}
{"ref-id":"L4539","title":"Electronic Medicines Compendium: Loteprednol etabonate Monograph","url":"https://www.medicines.org.uk/emc/product/6212","parent_key":"BE0002638"}
{"ref-id":"L3858","title":"NCI/NIH","url":"https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47705&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null","parent_key":"BE0002638"}
{"ref-id":"L6892","title":"Allergen monograph, Bimatoprost","url":"https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf","parent_key":"BE0002638"}
{"ref-id":"L6892","title":"Allergen monograph, Bimatoprost","url":"https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf","parent_key":"BE0002362"}
{"ref-id":"L8015","title":"Tiagabine FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020646s017lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L12342","title":"FDA Approved Products: Numbrino (cocaine hydrochloride) nasal solution","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209575s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8018","title":"Tinidazole FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4596","title":"CYP table","url":"https://drug-interactions.medicine.iu.edu/Clinical-Table.aspx","parent_key":"BE0002793"}
{"ref-id":"L9269","title":"FDA Approved Drug Products: Almotriptan Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021001s015lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L9269","title":"FDA Approved Drug Products: Almotriptan Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021001s015lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L8021","title":"FDA label, cyclobenzaprine","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/017821s045lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L11139","title":"FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L11545","title":"FDA Approved Drug Products: Wixela Inhub Fluticasone and Salmeterol Inhalation Powder","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208891Orig1s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11548","title":"FDA Approved Drug Products: Serevent Diskus Salmeterol Inhalation Powder","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11551","title":"FDA Approved Drug Products: Airduo Respiclick Fluticasone and Salmeterol Inhalation Powder","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208799s001lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11557","title":"FDA Approved Drug Products: Advair Diskus Fluticasone and Salmeterol Inhalation Powder","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021077s061lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8024","title":"Fluvestrant FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021344s015lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L2905","title":"Drug Interactions & Labeling - FDA","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2","parent_key":"BE0002793"}
{"ref-id":"L4515","title":"UMN Interaction Table, CYP450","url":"https://www.d.umn.edu/~jfitzake/Lectures/DMED/TAA/Q_A/CYP450InteractionTable.htm","parent_key":"BE0002793"}
{"ref-id":"L7913","title":"FDA Label: Hydrocodone Tab ER","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L7913","title":"FDA Label: Hydrocodone Tab ER","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L3588","title":"telmisartan - Drug Summary","url":"http://www.pdr.net/drug-summary/Micardis-telmisartan-1320","parent_key":"BE0003536"}
{"ref-id":"L4575","title":"Alosteron","url":"https://www.drugs.com/ppa/alosetron.html","parent_key":"BE0002433"}
{"ref-id":"L8027","title":"Alosetron FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21107s5lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8324","title":"LOTRONEX\u001a (alosetron hydrochloride) Tablets - FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21107lbl.pdf","parent_key":"BE0003533"}
{"ref-id":"L3583","title":"Telithromycin FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021144s013lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10986","title":"FDA Approved Drug Products: Perforomist\u001a inhalation solution","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L10986","title":"FDA Approved Drug Products: Perforomist\u001a inhalation solution","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L10986","title":"FDA Approved Drug Products: Perforomist\u001a inhalation solution","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L10986","title":"FDA Approved Drug Products: Perforomist\u001a inhalation solution","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf","parent_key":"BE0003336"}
{"ref-id":"L10986","title":"FDA Approved Drug Products: Perforomist\u001a inhalation solution","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf","parent_key":"BE0003538"}
{"ref-id":"L10986","title":"FDA Approved Drug Products: Perforomist\u001a inhalation solution","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf","parent_key":"BE0003679"}
{"ref-id":"L8354","title":"Hydroxyurea - National Toxicology Program - NIH","url":"https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/hydroxyurea_508.pdf","parent_key":"BE0002363"}
{"ref-id":"L11623","title":"FDA Approved Drug Products: Femara Letrozole Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11626","title":"FDA Approved Drug Products: Kisquali Femara Co-Pack Letrozole and Ribociclib Succinate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209935s006lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11623","title":"FDA Approved Drug Products: Femara Letrozole Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf","parent_key":"BE0003336"}
{"ref-id":"L11626","title":"FDA Approved Drug Products: Kisquali Femara Co-Pack Letrozole and Ribociclib Succinate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209935s006lbl.pdf","parent_key":"BE0003336"}
{"ref-id":"L11623","title":"FDA Approved Drug Products: Femara Letrozole Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L11626","title":"FDA Approved Drug Products: Kisquali Femara Co-Pack Letrozole and Ribociclib Succinate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209935s006lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L11277","title":"FDA Approved Drug Products: Intuniv Guanfacine Hydrochloride Extended Release Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s019lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8171","title":"Felodipine - LiverTox - NIH","url":"https://livertox.nih.gov/Felodipine.htm","parent_key":"BE0002638"}
{"ref-id":"L179","title":"Link","url":"https://www.pharmgkb.org/pathway/PA2040","parent_key":"BE0003539"}
{"ref-id":"L8588","title":"FDA Approved Drug Products: Fenofibrate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L8591","title":"FDA Approved Drug Products: Fenofibrate Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L8588","title":"FDA Approved Drug Products: Fenofibrate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L8591","title":"FDA Approved Drug Products: Fenofibrate Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L8588","title":"FDA Approved Drug Products: Fenofibrate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf","parent_key":"BE0003336"}
{"ref-id":"L8591","title":"FDA Approved Drug Products: Fenofibrate Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf","parent_key":"BE0003336"}
{"ref-id":"L4031","title":"The Effect of Cytochrome P450 Metabolism on Drug Response, Interactions, and Adverse Effects","url":"https://www.aafp.org/afp/2007/0801/p391.html","parent_key":"BE0002433"}
{"ref-id":"L4519","title":"Rifampicin","url":"http://bioinformatics.charite.de/transformer/index.php?site=fullinfo","parent_key":"BE0003536"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0003612"}
{"ref-id":"L2681","title":"Kegg","url":"http://www.genome.jp/dbget-bin/www_bget?dr:D02268","parent_key":"BE0002638"}
{"ref-id":"L8648","title":"Ditropan XL FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020897s037lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L7535","title":"Physician Guidelines: Drugs Metabolized by Cytochrome P450\u001as","url":"http://ildcare.eu/Downloads/artseninfo/Drugs_metabolized_by_CYP450s.pdf","parent_key":"BE0002363"}
{"ref-id":"L3424","title":"Atazanavir FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L3424","title":"Atazanavir FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L3846","title":"Atorvastatin FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s057lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L13616","title":"FDA Approved Drug Products: Sabril (vigabatrin) for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020427s021,022006s023lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L9022","title":"Zoloft, PDR","url":"https://www.pdr.net/drug-summary/Zoloft-sertraline-hydrochloride-474.3608","parent_key":"BE0003536"}
{"ref-id":"L9022","title":"Zoloft, PDR","url":"https://www.pdr.net/drug-summary/Zoloft-sertraline-hydrochloride-474.3608","parent_key":"BE0002793"}
{"ref-id":"L9188","title":"Sertraline pathway","url":"https://www.pharmgkb.org/pathway/PA166181117","parent_key":"BE0003533"}
{"ref-id":"L14021","title":"FDA Approved Drug Products: Oravig (miconazole) buccal tablet","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022404s005lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8267","title":"ADALAT\u001a XL\u001a (Nifedipine extended-release tablets) Product Monograph","url":"https://www.bayer.ca/omr/online/adalat-xl-pm-eng.pdf","parent_key":"BE0002433"}
{"ref-id":"L8267","title":"ADALAT\u001a XL\u001a (Nifedipine extended-release tablets) Product Monograph","url":"https://www.bayer.ca/omr/online/adalat-xl-pm-eng.pdf","parent_key":"BE0003336"}
{"ref-id":"L166","title":"Drug Interactions: Cytochrome P450 Drug Interaction Table","url":"http://medicine.iupui.edu/clinpharm/ddis/table.aspx","parent_key":"BE0002638"}
{"ref-id":"L2908","title":"Electronic Medicines Compendium Amiodarone 100mg Tablets","url":"https://www.medicines.org.uk/emc/product/6019/smpc","parent_key":"BE0002638"}
{"ref-id":"L3561","title":"FDA Approved Drug Products: Cordarone (amiodarone HCl) tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018972s042lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L3561","title":"FDA Approved Drug Products: Cordarone (amiodarone HCl) tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018972s042lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L166","title":"Drug Interactions: Cytochrome P450 Drug Interaction Table","url":"http://medicine.iupui.edu/clinpharm/ddis/table.aspx","parent_key":"BE0002363"}
{"ref-id":"L166","title":"Drug Interactions: Cytochrome P450 Drug Interaction Table","url":"http://medicine.iupui.edu/clinpharm/ddis/table.aspx","parent_key":"BE0002793"}
{"ref-id":"L166","title":"Drug Interactions: Cytochrome P450 Drug Interaction Table","url":"http://medicine.iupui.edu/clinpharm/ddis/table.aspx","parent_key":"BE0002433"}
{"ref-id":"L3561","title":"FDA Approved Drug Products: Cordarone (amiodarone HCl) tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018972s042lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L6256","title":"Avodart (dutasteride capsules) - Product Monograph","url":"https://ca.gsk.com/media/588688/avodart.pdf","parent_key":"BE0002362"}
{"ref-id":"L4559","title":"Bicalutamide","url":"http://www.pdr.net/drug-summary/Casodex-bicalutamide-2161","parent_key":"BE0003536"}
{"ref-id":"L3856","title":"NCI/NIH","url":"https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47684&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null","parent_key":"BE0002638"}
{"ref-id":"L3884","title":"University of Liverpool","url":"https://hep-druginteractions.org/interactions/1205/all","parent_key":"BE0002638"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0002887"}
{"ref-id":"L11416","title":"FDA Approved Drug Products: Actos (pioglitazone) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf","parent_key":"BE0003543"}
{"ref-id":"L8180","title":"Carvedilol Therapy and CYP2D6 Genotype","url":"https://www.ncbi.nlm.nih.gov/books/NBK518573/","parent_key":"BE0002793"}
{"ref-id":"L8180","title":"Carvedilol Therapy and CYP2D6 Genotype","url":"https://www.ncbi.nlm.nih.gov/books/NBK518573/","parent_key":"BE0002363"}
{"ref-id":"L8180","title":"Carvedilol Therapy and CYP2D6 Genotype","url":"https://www.ncbi.nlm.nih.gov/books/NBK518573/","parent_key":"BE0002638"}
{"ref-id":"L8180","title":"Carvedilol Therapy and CYP2D6 Genotype","url":"https://www.ncbi.nlm.nih.gov/books/NBK518573/","parent_key":"BE0003533"}
{"ref-id":"L4604","title":"Get to Know an Enzyme: CYP1A2","url":"https://www.pharmacytimes.com/publications/issue/2007/2007-11/2007-11-8279","parent_key":"BE0002433"}
{"ref-id":"L8315","title":"Health Canada Product Monograph: Bupropion sustained-release tablets","url":"https://pdf.hres.ca/dpd_pm/00018678.PDF","parent_key":"BE0002793"}
{"ref-id":"L92","title":"Link","url":"http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Flutamide.htm","parent_key":"BE0002638"}
{"ref-id":"L4424","title":"PHENOBARBITAL SODIUM INJECTION Prescribing Information - Sandoz Canada","url":"https://www.sandoz.ca/sites/www.sandoz.ca/files/Phenobarbital%20Product%20Monograph.pdf","parent_key":"BE0002638"}
{"ref-id":"L8513","title":"FDA Approved Drug Products: Lexapro (escitalopram) for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021323s051,021365s036lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8516","title":"DPD Approved Drugs: Escitalopram","url":"https://www.lundbeck.com/upload/ca/en/files/pdf/pm/Cipralex%20JUN2018_PM_E_clean.pdf","parent_key":"BE0002638"}
{"ref-id":"L8513","title":"FDA Approved Drug Products: Lexapro (escitalopram) for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021323s051,021365s036lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L8516","title":"DPD Approved Drugs: Escitalopram","url":"https://www.lundbeck.com/upload/ca/en/files/pdf/pm/Cipralex%20JUN2018_PM_E_clean.pdf","parent_key":"BE0002363"}
{"ref-id":"L8513","title":"FDA Approved Drug Products: Lexapro (escitalopram) for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021323s051,021365s036lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L8516","title":"DPD Approved Drugs: Escitalopram","url":"https://www.lundbeck.com/upload/ca/en/files/pdf/pm/Cipralex%20JUN2018_PM_E_clean.pdf","parent_key":"BE0003536"}
{"ref-id":"L12135","title":"Health Canada Approved Drug Products: Domperidone Oral Tablets","url":"https://pdf.hres.ca/dpd_pm/00029814.PDF","parent_key":"BE0002638"}
{"ref-id":"L8396","title":"Domperidone 10mg Tablets - Summary of Product Characteristics - eMC","url":"https://www.medicines.org.uk/emc/product/556/smpc","parent_key":"BE0002433"}
{"ref-id":"L8042","title":"Australian Government: Public Assessment Report for Brinzolamide/ Timolol Maleate","url":"https://www.tga.gov.au/sites/default/files/auspar-timolol.pdf","parent_key":"BE0002638"}
{"ref-id":"L6865","title":"IMOVANE (Zopiclone) Product Monograph","url":"http://products.sanofi.ca/en/imovane.pdf","parent_key":"BE0002638"}
{"ref-id":"L6865","title":"IMOVANE (Zopiclone) Product Monograph","url":"http://products.sanofi.ca/en/imovane.pdf","parent_key":"BE0002887"}
{"ref-id":"L8195","title":"Bromocriptine Monograph - BC Cancer","url":"http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Bromocriptine_monograph_1Nov07.pdf","parent_key":"BE0002638"}
{"ref-id":"L4734","title":"Parlodel (bromocriptine mesylate) - FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L3995","title":"Priftin (Rifapentine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8033","title":"FDA Approved Drug Products: Mitoxantrone","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019297s035lbl.pdf","parent_key":"BE0003533"}
{"ref-id":"L8378","title":"Lomustine Drug Monograph - BC Cancer","url":"http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Lomustine_monograph.pdf","parent_key":"BE0002363"}
{"ref-id":"L8198","title":"BIAXIN (clarithromycin) - Drug Monograph","url":"https://www.mylan.ca/-/media/mylanca/documents/english/product%20pdf/biaxin-pm-2016-05-31.pdf","parent_key":"BE0002638"}
{"ref-id":"L8863","title":"FDA Approved Drug Products: Arimidex (anastrozole) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020541s031lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8869","title":"DPD Approved Drugs: Anastrozole","url":"https://pdf.hres.ca/dpd_pm/00037304.PDF","parent_key":"BE0002638"}
{"ref-id":"L8863","title":"FDA Approved Drug Products: Arimidex (anastrozole) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020541s031lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L8869","title":"DPD Approved Drugs: Anastrozole","url":"https://pdf.hres.ca/dpd_pm/00037304.PDF","parent_key":"BE0002887"}
{"ref-id":"L8863","title":"FDA Approved Drug Products: Arimidex (anastrozole) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020541s031lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L8869","title":"DPD Approved Drugs: Anastrozole","url":"https://pdf.hres.ca/dpd_pm/00037304.PDF","parent_key":"BE0002433"}
{"ref-id":"L8863","title":"FDA Approved Drug Products: Arimidex (anastrozole) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020541s031lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L8869","title":"DPD Approved Drugs: Anastrozole","url":"https://pdf.hres.ca/dpd_pm/00037304.PDF","parent_key":"BE0002793"}
{"ref-id":"L10601","title":"FDA Approved Drug Products: Entocort Budesonide Oral Extended Release Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021324s018lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10604","title":"FDA Approved Drug Products: Ortikos Budesonide Oral Extended Release Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211929s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10607","title":"FDA Approved Drug Products: Pulmicort Budesonide Inhalation Powder","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021949s013lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10613","title":"FDA Approved Drug Products: Pulmicort Budesonide Inhalation Suspension","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020929s052lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10616","title":"FDA Approved Drug Products: Rhinocort Budesonide Nasal Metered Spray","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020746Orig1s037lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10619","title":"FDA Approved Drug Products: Symbicort (budesonide/formoterol fumarate) inhalation aerosol","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s042lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10622","title":"FDA Approved Drug Products: Uceris Budesonide Oral Extended Release Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203634s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10625","title":"FDA Approved Drug Products: Uceris Budesonide Rectal Aerosol Foam","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205613s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10184","title":"Dexamethasone monograph, Boehringer Ingelheim","url":"https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Roxane/Dexamethasone/Dexamethasone%20Tablets%20Solution%20and%20Intensol.pdf","parent_key":"BE0002638"}
{"ref-id":"L10710","title":"FDA Approved Drug Products: Hemady Dexamethasone Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211379s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8201","title":"Aripiprazole Therapy and CYP2D6 Genotype","url":"https://www.ncbi.nlm.nih.gov/books/NBK385288/","parent_key":"BE0002638"}
{"ref-id":"L163","title":"The P450 Program","url":"http://mhc.com/Cytochromes/","parent_key":"BE0003536"}
{"ref-id":"L4574","title":"PDR, Anafranil","url":"http://www.pdr.net/drug-summary/Anafranil-clomipramine-hydrochloride-678","parent_key":"BE0002433"}
{"ref-id":"L163","title":"The P450 Program","url":"http://mhc.com/Cytochromes/","parent_key":"BE0002638"}
{"ref-id":"L4141","title":"Tykerb (Lapatinib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4141","title":"Tykerb (Lapatinib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L2938","title":"Get to know an Enzyme: CYP2C8","url":"http://www.hanstenandhorn.com/hh-article-December-2011.pdf","parent_key":"BE0002887"}
{"ref-id":"L4141","title":"Tykerb (Lapatinib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L4141","title":"Tykerb (Lapatinib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L9227","title":"FDA Approved Drug Products: Prezista (darunavir) oral tablets/suspension","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L9227","title":"FDA Approved Drug Products: Prezista (darunavir) oral tablets/suspension","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L3954","title":"Invega (Paliperidone) FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4137","title":"Invega Trinza (Paliperidone palmitate) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207946s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4137","title":"Invega Trinza (Paliperidone palmitate) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207946s000lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L3954","title":"Invega (Paliperidone) FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L8138","title":"Colchicine FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022352s017lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10187","title":"Amprenavir FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022116s023_21548-s39lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L3141","title":"Fosphenytoin sodium - Drug Summary - Prescribers Digital Reference - Drug Interactions","url":"http://www.pdr.net/drug-summary/Cerebyx-fosphenytoin-sodium-3925","parent_key":"BE0002433"}
{"ref-id":"L3136","title":"PDR","url":"http://www.pdr.net/drug-summary/Necon-ethinyl-estradiol-norethindrone----mestranol-norethindrone-2049","parent_key":"BE0002638"}
{"ref-id":"L10205","title":"Quinupristin FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050748s008,050747s008lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10247","title":"EMA assessment, gingko biloba","url":"https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-ginkgo-biloba-l-folium_en.pdf","parent_key":"BE0002638"}
{"ref-id":"L8192","title":"Pharmacology review, FDA","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204820Orig1s000PharmR.pdf","parent_key":"BE0002638"}
{"ref-id":"L7997","title":"Angeliq EU label","url":"http://mri.cts-mrp.eu/download/NL_H_0380_001_FinalSPC.pdf","parent_key":"BE0002638"}
{"ref-id":"L10199","title":"Zocor PI monograph","url":"https://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf","parent_key":"BE0002638"}
{"ref-id":"L1162","title":"Empowerpharmacy","url":"https://www.empowerpharmacy.com/drugs/testosterone-propionate-injection.html","parent_key":"BE0002638"}
{"ref-id":"L4594","title":"Theophylline metabolic pathway","url":"https://www.pharmgkb.org/pathway/PA165958541","parent_key":"BE0002433"}
{"ref-id":"L8306","title":"Lectopam monograph","url":"https://www.rochecanada.com/PMs/Lectopam/Lectopam_PM_E.pdf","parent_key":"BE0002433"}
{"ref-id":"L4564","title":"PubChem: Liotrix Profile","url":"https://pubchem.ncbi.nlm.nih.gov/compound/Liotrix#section=Top","parent_key":"BE0002887"}
{"ref-id":"L7511","title":"FDA Approved Drug Products: Solifenacin Succinate Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021518s018lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11163","title":"FDA Approved Drug Products: Kaletra (lopinavir/ritonavir) for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021251s058,021906s053lbl.pdf","parent_key":"BE0004866"}
{"ref-id":"L4583","title":"Thiothixene","url":"http://www.pdr.net/drug-summary/Thiothixene-thiothixene-2297","parent_key":"BE0002433"}
{"ref-id":"L4584","title":"Daily Med, Genistein","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=899ea7ce-0996-4635-9545-1e07091cf400","parent_key":"BE0002433"}
{"ref-id":"L867","title":"Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review","url":"https://www.pmda.go.jp/files/000153624.pdf","parent_key":"BE0002887"}
{"ref-id":"L867","title":"Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review","url":"https://www.pmda.go.jp/files/000153624.pdf","parent_key":"BE0002793"}
{"ref-id":"L867","title":"Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review","url":"https://www.pmda.go.jp/files/000153624.pdf","parent_key":"BE0003543"}
{"ref-id":"L867","title":"Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review","url":"https://www.pmda.go.jp/files/000153624.pdf","parent_key":"BE0002638"}
{"ref-id":"L867","title":"Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review","url":"https://www.pmda.go.jp/files/000153624.pdf","parent_key":"BE0003536"}
{"ref-id":"L3817","title":"NHS","url":"http://www.barnsleyccg.nhs.uk/CCG%20Downloads/Members/Medicines%20management/Prescribing%20Guidelines/Prostate%20cancer%20Amber%20with%20guidance%20April%202015.pdf","parent_key":"BE0002638"}
{"ref-id":"L3566","title":"Dronedarone FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022425s010lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L7985","title":"FDA Approved Drug Products: Nebivolol Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L4107","title":"Tasigna\u001a (nilotinib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8492","title":"FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206334s005lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8492","title":"FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206334s005lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L8495","title":"EMA Assessment Report: Orbactiv","url":"https://www.ema.europa.eu/en/documents/assessment-report/orbactiv-epar-public-assessment-report_en.pdf","parent_key":"BE0002363"}
{"ref-id":"L2801","title":"FDA reports","url":"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM602419.pdf","parent_key":"BE0002363"}
{"ref-id":"L4590","title":"Lofexidine","url":"https://www.drugs.com/ppa/lofexidine.html","parent_key":"BE0002433"}
{"ref-id":"L2801","title":"FDA reports","url":"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM602419.pdf","parent_key":"BE0003536"}
{"ref-id":"L757","title":"FDA Cross discipline team leader review","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206256Orig1s000CrossR.pdf","parent_key":"BE0002433"}
{"ref-id":"L925","title":"EMA Product Label","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002720/WC500171813.pdf","parent_key":"BE0003538"}
{"ref-id":"L8057","title":"Pretomanid briefing document, FDA","url":"https://www.fda.gov/media/127592/download","parent_key":"BE0002638"}
{"ref-id":"L8048","title":"Pretomanid FDA label, August 2019","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L161","title":"Link","url":"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515","parent_key":"BE0003609"}
{"ref-id":"L161","title":"Link","url":"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515","parent_key":"BE0003606"}
{"ref-id":"L161","title":"Link","url":"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515","parent_key":"BE0002638"}
{"ref-id":"L7501","title":"FDA label, Otezla","url":"https://media.celgene.com/content/uploads/otezla-pi.pdf","parent_key":"BE0002638"}
{"ref-id":"L7501","title":"FDA label, Otezla","url":"https://media.celgene.com/content/uploads/otezla-pi.pdf","parent_key":"BE0003336"}
{"ref-id":"L7501","title":"FDA label, Otezla","url":"https://media.celgene.com/content/uploads/otezla-pi.pdf","parent_key":"BE0002433"}
{"ref-id":"L12633","title":"FDA Approved Products: Ocaliva (obeticholic acid) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L10860","title":"CAPLYTA\u001a","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L10860","title":"CAPLYTA\u001a","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L10653","title":"FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf","parent_key":"BE0003679"}
{"ref-id":"L10653","title":"FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf","parent_key":"BE0003681"}
{"ref-id":"L10653","title":"FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf","parent_key":"BE0003533"}
{"ref-id":"L10653","title":"FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf","parent_key":"BE0003336"}
{"ref-id":"L10653","title":"FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L10653","title":"FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L10653","title":"FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10653","title":"FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L10653","title":"FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L4507","title":"Drugs.com Lacosamide Monograph","url":"https://www.drugs.com/monograph/lacosamide.html","parent_key":"BE0003536"}
{"ref-id":"L12789","title":"FDA Approved Drug Products: Actemra Tocilizumab Intravenous or Subcutaneous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125276s127,125472s040lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L7694","title":"FDA Approved Drug Products: Levocetirizine Dihydrochloride Tablets and Oral Solution","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022064s038,022157s020lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L2922","title":"OLYSIO (simeprevir) capsules - FDA","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205123s012lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L4163","title":"Intelence (Etravirine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022187s008lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4093","title":"INLYTA\u001a (axitinib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4093","title":"INLYTA\u001a (axitinib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L4093","title":"INLYTA\u001a (axitinib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L4091","title":"CRESEMBA\u001a (isavuconazonium sulfate) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L212","title":"Link","url":"http://www.page-meeting.org/pdf_assets/2259-posterPAGE2008_SP.pdf","parent_key":"BE0002363"}
{"ref-id":"L8321","title":"COARTEM\u001a (artemether and lumefantrine) tablets, for oral use - FDA Label","url":"https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/coartem.pdf","parent_key":"BE0003549"}
{"ref-id":"L8321","title":"COARTEM\u001a (artemether and lumefantrine) tablets, for oral use - FDA Label","url":"https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/coartem.pdf","parent_key":"BE0002793"}
{"ref-id":"L8321","title":"COARTEM\u001a (artemether and lumefantrine) tablets, for oral use - FDA Label","url":"https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/coartem.pdf","parent_key":"BE0003536"}
{"ref-id":"L4357","title":"Pfizer Pristiq","url":"https://www.pfizermedicalinformation.ca/en-ca/pristiq/drug-interactions#","parent_key":"BE0002638"}
{"ref-id":"L167","title":"JEVTANA - cabazitaxel","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa","parent_key":"BE0002638"}
{"ref-id":"L167","title":"JEVTANA - cabazitaxel","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa","parent_key":"BE0002362"}
{"ref-id":"L167","title":"JEVTANA - cabazitaxel","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa","parent_key":"BE0002887"}
{"ref-id":"L3849","title":"NCI/NIH","url":"https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47552&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null","parent_key":"BE0002638"}
{"ref-id":"L11067","title":"EMA Summary of Product Characteristics: Dynastat (parecoxib) oral tablets","url":"https://www.ema.europa.eu/en/documents/product-information/dynastat-epar-product-information_en.pdf","parent_key":"BE0002638"}
{"ref-id":"L11067","title":"EMA Summary of Product Characteristics: Dynastat (parecoxib) oral tablets","url":"https://www.ema.europa.eu/en/documents/product-information/dynastat-epar-product-information_en.pdf","parent_key":"BE0002793"}
{"ref-id":"L3990","title":"Online Health","url":"http://pastande.org/diet-drug-porfimer-sodium-safe-effective-study-finds/","parent_key":"BE0002638"}
{"ref-id":"L3686","title":"Lurasidone HCl FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603lbls10s11.pdf","parent_key":"BE0002638"}
{"ref-id":"L14201","title":"FDA Approved Drug Products: Brilinta Ticagrelor Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022433s028lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L6979","title":"FDA Approved Drug Products: Kalydeco (ivacaftor)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203188s029,207925s008lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L6979","title":"FDA Approved Drug Products: Kalydeco (ivacaftor)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203188s029,207925s008lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L4089","title":"Xalkori (Crizotinib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s021lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4089","title":"Xalkori (Crizotinib) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s021lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L12651","title":"FDA Approved Products: Gilenya (fingolimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf","parent_key":"BE0004728"}
{"ref-id":"L12690","title":"European Medicines Agency Public Assessment Report: Gilenya (fingolimod)","url":"https://www.ema.europa.eu/en/documents/assessment-report/gilenya-epar-public-assessment-report_en.pdf","parent_key":"BE0003533"}
{"ref-id":"L12651","title":"FDA Approved Products: Gilenya (fingolimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf","parent_key":"BE0004727"}
{"ref-id":"L1742","title":"Cancer Care Ontario Formulary","url":"https://www.cancercareontario.ca/sites/ccocancercare/files/brentuximab%20vedotin.pdf","parent_key":"BE0002638"}
{"ref-id":"L3473","title":"FDA Approved Drug Products: VICTRELIS (boceprevir) Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4083","title":"Fycompa (Perampanel) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4083","title":"Fycompa (Perampanel) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L4083","title":"Fycompa (Perampanel) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L10196","title":"Enzalutamide FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L3844","title":"Blog","url":"http://sbolot.org/drug-results-for-formestane-chloride/","parent_key":"BE0002638"}
{"ref-id":"L3868","title":"FDA reports","url":"https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM421134.pdf","parent_key":"BE0002638"}
{"ref-id":"L10181","title":"Dabrafenib FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202806s006lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L2916","title":"luliconazole - Drug Summary PDR","url":"http://www.pdr.net/drug-summary/Luzu-luliconazole-3401","parent_key":"BE0002638"}
{"ref-id":"L2916","title":"luliconazole - Drug Summary PDR","url":"http://www.pdr.net/drug-summary/Luzu-luliconazole-3401","parent_key":"BE0003536"}
{"ref-id":"L13994","title":"FDA Approved Products: Tekturna (Aliskiren) oral tablets and pellets","url":"https://www.tekturna.com/wp-content/uploads/2017/11/Tekturna_PCR-1.pdf","parent_key":"BE0002638"}
{"ref-id":"L13688","title":"FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf","parent_key":"BE0003679"}
{"ref-id":"L13688","title":"FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf","parent_key":"BE0003677"}
{"ref-id":"L13688","title":"FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf","parent_key":"BE0003538"}
{"ref-id":"L4513","title":"FDA reports","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000ClinPharmR.pdf","parent_key":"BE0002638"}
{"ref-id":"L2942","title":"Cobicistat versus ritonavir boosting and differences in the drug\u001adrug interaction profiles with co-medications","url":"https://academic.oup.com/jac/article/71/7/1755/1750409","parent_key":"BE0002363"}
{"ref-id":"L3432","title":"Cobicistat FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203094s008lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4063","title":"Brintellix (Vortioxetine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L4063","title":"Brintellix (Vortioxetine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L4063","title":"Brintellix (Vortioxetine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L4063","title":"Brintellix (Vortioxetine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L4063","title":"Brintellix (Vortioxetine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L4063","title":"Brintellix (Vortioxetine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf","parent_key":"BE0003336"}
{"ref-id":"L4063","title":"Brintellix (Vortioxetine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L4063","title":"Brintellix (Vortioxetine) FDA Label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L8453","title":"FDA Approved Drugs: Nintedanib","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205832s010lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L880","title":"European Medicines Agency (EMA): DIACOMIT Summary of Product Characteristics","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf","parent_key":"BE0003536"}
{"ref-id":"L880","title":"European Medicines Agency (EMA): DIACOMIT Summary of Product Characteristics","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf","parent_key":"BE0002363"}
{"ref-id":"L880","title":"European Medicines Agency (EMA): DIACOMIT Summary of Product Characteristics","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf","parent_key":"BE0002638"}
{"ref-id":"L4524","title":"Eslicarbazepine, PDR","url":"http://m.pdr.net/drug-summary/Aptiom-eslicarbazepine-acetate-3400","parent_key":"BE0003536"}
{"ref-id":"L877","title":"Sanofi Canada: ZUACTA (zucapsaicin cream) product monograph","url":"http://products.sanofi.ca/en/zuacta.pdf","parent_key":"BE0002433"}
{"ref-id":"L877","title":"Sanofi Canada: ZUACTA (zucapsaicin cream) product monograph","url":"http://products.sanofi.ca/en/zuacta.pdf","parent_key":"BE0003533"}
{"ref-id":"L931","title":"Bayer Inc: VISANNE (2mg dienogest tablets) Product Monograph","url":"http://www.bayer.ca/static/documents/news/en/VISANNE-PM-EN-19JUN2015-182736.pdf","parent_key":"BE0002638"}
{"ref-id":"L884","title":"World Health Organization: Etizolam (INN) Pre-Review Report","url":"https://erowid.org/pharms/etizolam/etizolam_article1_who_2016.pdf","parent_key":"BE0002638"}
{"ref-id":"L1178","title":"Jstage","url":"https://www.jstage.jst.go.jp/article/jsma1939/45/6/45_6_739/_pdf","parent_key":"BE0004866"}
{"ref-id":"L1341","title":"Zotepine monograph","url":"http://www.drugfuture.com/mt/zotepine.pdf","parent_key":"BE0002638"}
{"ref-id":"L1342","title":"KEGG","url":"http://www.genome.jp/dbget-bin/www_bget?D01562","parent_key":"BE0002638"}
{"ref-id":"L1379","title":"DRUG: Azelnidipine","url":"http://www.genome.jp/dbget-bin/www_bget?D01145","parent_key":"BE0002638"}
{"ref-id":"L1442","title":"Pharmacokinetic Interaction between Warfarin and Efonidipine in Rats","url":"https://pdfs.semanticscholar.org/058d/a3935a5736ea1244a3b6f2e1a6348c792146.pdf","parent_key":"BE0002638"}
{"ref-id":"L1126","title":"Lacidipine Summary of Product Characteristics","url":"http://mri.cts-mrp.eu/download/NL_H_2992_002_FinalSPC.pdf","parent_key":"BE0002638"}
{"ref-id":"L1490","title":"Amlodipine Metabolism in Human Liver Microsomes and Roles of CYP3A4/5 in the Dihydropyridine Dehydrogenation","url":"http://dmd.aspetjournals.org/content/42/2/245","parent_key":"BE0002638"}
{"ref-id":"L3675","title":"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf","parent_key":"BE0003538"}
{"ref-id":"L3675","title":"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L12513","title":"In Vitro Assessment of Methylene Blue Hydrate as a Multiple CYP450 Inhibitor and a Mechanism-Based Inhibitor","url":"https://www.researchgate.net/publication/268145483_In_Vitro_Assessment_of_Methylene_Blue_Hydrate_as_a_Multiple_CYP450_Inhibitor_and_a_Mechanism-Based_Inhibitor","parent_key":"BE0002433"}
{"ref-id":"L12513","title":"In Vitro Assessment of Methylene Blue Hydrate as a Multiple CYP450 Inhibitor and a Mechanism-Based Inhibitor","url":"https://www.researchgate.net/publication/268145483_In_Vitro_Assessment_of_Methylene_Blue_Hydrate_as_a_Multiple_CYP450_Inhibitor_and_a_Mechanism-Based_Inhibitor","parent_key":"BE0003549"}
{"ref-id":"L3675","title":"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L12153","title":"NIH StatPearls: Cholesterol levels","url":"https://www.ncbi.nlm.nih.gov/books/NBK542294/","parent_key":"BE0002887"}
{"ref-id":"L3675","title":"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L12153","title":"NIH StatPearls: Cholesterol levels","url":"https://www.ncbi.nlm.nih.gov/books/NBK542294/","parent_key":"BE0002793"}
{"ref-id":"L3675","title":"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L12153","title":"NIH StatPearls: Cholesterol levels","url":"https://www.ncbi.nlm.nih.gov/books/NBK542294/","parent_key":"BE0003536"}
{"ref-id":"L3675","title":"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L12153","title":"NIH StatPearls: Cholesterol levels","url":"https://www.ncbi.nlm.nih.gov/books/NBK542294/","parent_key":"BE0002638"}
{"ref-id":"L3675","title":"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L12153","title":"NIH StatPearls: Cholesterol levels","url":"https://www.ncbi.nlm.nih.gov/books/NBK542294/","parent_key":"BE0002362"}
{"ref-id":"L3675","title":"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L3675","title":"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L934","title":"UFT (uracil/tegafur) capsules_Product information","url":"https://hemonc.org/docs/packageinsert/uraciltegafur.pdf","parent_key":"BE0003336"}
{"ref-id":"L14099","title":"FDA Approved Drug Products: Artesunate Intravenous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf","parent_key":"BE0003679"}
{"ref-id":"L14099","title":"FDA Approved Drug Products: Artesunate Intravenous Injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf","parent_key":"BE0003538"}
{"ref-id":"L891","title":"Artesunate Product Information","url":"https://extranet.who.int/prequal/sites/default/files/documents/MA051part4v2.pdf","parent_key":"BE0003336"}
{"ref-id":"L6277","title":"FDA Approved Drug Products: Bictegravir, Emtricitabine, and Tenofovir Alafenamide Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L1503","title":"Pharmacokinetics Basics- Absorption, Distribution, Metabolism and Excretion","url":"https://www.ndrugs.com/?s=vayarin&t=actions","parent_key":"BE0003533"}
{"ref-id":"L3840","title":"NCI/NIH","url":"https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C65730&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null","parent_key":"BE0002638"}
{"ref-id":"L3853","title":"NCI/NIH","url":"https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C66096&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null","parent_key":"BE0002638"}
{"ref-id":"L2401","title":"FDA reports","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205060Orig1s000PharmR.pdf","parent_key":"BE0004866"}
{"ref-id":"L2401","title":"FDA reports","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205060Orig1s000PharmR.pdf","parent_key":"BE0004727"}
{"ref-id":"L1790","title":"PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies","url":"http://dmd.aspetjournals.org/content/dmd/35/1/9.full.pdf","parent_key":"BE0000421"}
{"ref-id":"L1807","title":"Health partners","url":"https://www.healthpartners.com/ucm/groups/public/@hp/@public/@ime/@content/documents/documents/cntrb_031044.pdf","parent_key":"BE0002363"}
{"ref-id":"L2684","title":"Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells","url":"https://www.sciencedirect.com/science/article/pii/S0887233313000672","parent_key":"BE0003543"}
{"ref-id":"L2684","title":"Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells","url":"https://www.sciencedirect.com/science/article/pii/S0887233313000672","parent_key":"BE0001111"}
{"ref-id":"L9776","title":"Lesinurad FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10253","title":"Zepatier FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208261s002lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L2293","title":"Australian Public Assessment Report: Asunaprevir","url":"https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf","parent_key":"BE0002638"}
{"ref-id":"L2287","title":"Australian Product Information: Sunvepra (Asunaprevir) Capsules","url":"http://www.medicines.org.au/files/bqpsunve.pdf","parent_key":"BE0002638"}
{"ref-id":"L2293","title":"Australian Public Assessment Report: Asunaprevir","url":"https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf","parent_key":"BE0002362"}
{"ref-id":"L2287","title":"Australian Product Information: Sunvepra (Asunaprevir) Capsules","url":"http://www.medicines.org.au/files/bqpsunve.pdf","parent_key":"BE0002362"}
{"ref-id":"L2293","title":"Australian Public Assessment Report: Asunaprevir","url":"https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf","parent_key":"BE0003336"}
{"ref-id":"L2293","title":"Australian Public Assessment Report: Asunaprevir","url":"https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf","parent_key":"BE0003549"}
{"ref-id":"L2293","title":"Australian Public Assessment Report: Asunaprevir","url":"https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf","parent_key":"BE0002793"}
{"ref-id":"L2293","title":"Australian Public Assessment Report: Asunaprevir","url":"https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf","parent_key":"BE0003536"}
{"ref-id":"L2293","title":"Australian Public Assessment Report: Asunaprevir","url":"https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf","parent_key":"BE0002363"}
{"ref-id":"L2287","title":"Australian Product Information: Sunvepra (Asunaprevir) Capsules","url":"http://www.medicines.org.au/files/bqpsunve.pdf","parent_key":"BE0002363"}
{"ref-id":"L769","title":"FDA Clinical Pharmacology and Biopharmaceutics Review","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000ClinPharmR.pdf","parent_key":"BE0002793"}
{"ref-id":"L2341","title":"EMA assessment report","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002790/WC500209538.pdf","parent_key":"BE0003536"}
{"ref-id":"L2341","title":"EMA assessment report","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002790/WC500209538.pdf","parent_key":"BE0002887"}
{"ref-id":"L2385","title":"\u001a-TOCOPHEROL \u001a-OXIDATION LOCALIZED TO RAT LIVER MITOCHONDRIA","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818260/","parent_key":"BE0004727"}
{"ref-id":"L2384","title":"Vitamin E Regulatory Mechanisms","url":"https://www.annualreviews.org/doi/abs/10.1146/annurev.nutr.27.061406.093819","parent_key":"BE0004727"}
{"ref-id":"L8528","title":"Vitamin E","url":"https://epdf.pub/vitamin-e-a-medical-dictionary-bibliography-and-annotated-research-guide-to-inte.html","parent_key":"BE0004727"}
{"ref-id":"L1407","title":"Deltyba, INN-Delamanid - European Medicines Agency - Europa EU","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002552/WC500166232.pdf","parent_key":"BE0002638"}
{"ref-id":"L1149","title":"EMA: Eurartesim Assessment Report","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf","parent_key":"BE0003538"}
{"ref-id":"L1149","title":"EMA: Eurartesim Assessment Report","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf","parent_key":"BE0003679"}
{"ref-id":"L1149","title":"EMA: Eurartesim Assessment Report","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf","parent_key":"BE0002363"}
{"ref-id":"L1149","title":"EMA: Eurartesim Assessment Report","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf","parent_key":"BE0003536"}
{"ref-id":"L12945","title":"FDA approved products: Tukysa (tucatinib) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L2953","title":"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers","url":"https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm","parent_key":"BE0004866"}
{"ref-id":"L12945","title":"FDA approved products: Tukysa (tucatinib) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf","parent_key":"BE0004866"}
{"ref-id":"L12852","title":"FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L12852","title":"FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L12852","title":"FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L12852","title":"FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf","parent_key":"BE0003533"}
{"ref-id":"L12852","title":"FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L12852","title":"FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf","parent_key":"BE0003677"}
{"ref-id":"L10241","title":"FDA Approved Drug Products: Calquence Acalabrutinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10241","title":"FDA Approved Drug Products: Calquence Acalabrutinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L10241","title":"FDA Approved Drug Products: Calquence Acalabrutinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf","parent_key":"BE0004866"}
{"ref-id":"L6814","title":"Symdeko FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L6829","title":"Monograph, Tezacaftor/Ivacaftor","url":"https://pdf.hres.ca/dpd_pm/00046145.PDF","parent_key":"BE0002638"}
{"ref-id":"L6814","title":"Symdeko FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L6829","title":"Monograph, Tezacaftor/Ivacaftor","url":"https://pdf.hres.ca/dpd_pm/00046145.PDF","parent_key":"BE0002362"}
{"ref-id":"L9338","title":"FDA Approved Drugs: Reyvow","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L8558","title":"FDA Approved Drugs: Tenapanor","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8558","title":"FDA Approved Drugs: Tenapanor","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L1000","title":"ema.europa","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004254/WC500230070.pdf","parent_key":"BE0002638"}
{"ref-id":"L4281","title":"Book section","url":"https://dokumen.tips/documents/drug-interactions-in-infectious-diseases-quinolones.html","parent_key":"BE0002433"}
{"ref-id":"L13347","title":"FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L13347","title":"FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf","parent_key":"BE0003539"}
{"ref-id":"L13347","title":"FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L12123","title":"FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L12132","title":"EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets","url":"https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf","parent_key":"BE0002638"}
{"ref-id":"L12123","title":"FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L12132","title":"EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets","url":"https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf","parent_key":"BE0003549"}
{"ref-id":"L12123","title":"FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L12132","title":"EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets","url":"https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf","parent_key":"BE0002363"}
{"ref-id":"L12132","title":"EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets","url":"https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf","parent_key":"BE0003679"}
{"ref-id":"L12132","title":"EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets","url":"https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf","parent_key":"BE0002362"}
{"ref-id":"L12123","title":"FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L12123","title":"FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L12132","title":"EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets","url":"https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf","parent_key":"BE0003533"}
{"ref-id":"L6700","title":"Deflazacort FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208684s003,208685s003lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L12144","title":"FDA Approved Products: Nexletol (bempedoic acid) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf","parent_key":"BE0003679"}
{"ref-id":"L9770","title":"Delafloxacin FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10863","title":"FDA Approved Drug Products: Dayvigo (lemborexant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10863","title":"FDA Approved Drug Products: Dayvigo (lemborexant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L10863","title":"FDA Approved Drug Products: Dayvigo (lemborexant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L10863","title":"FDA Approved Drug Products: Dayvigo (lemborexant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf","parent_key":"BE0004866"}
{"ref-id":"L8081","title":"FDA Label: Rozlytrek","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L6655","title":"New Mexico Cancer Alliance: Compassionate Use of Alpelisib","url":"https://clinicaltrials.gov/ProvidedDocs/82/NCT03941782/Prot_000.pdf","parent_key":"BE0002638"}
{"ref-id":"L6655","title":"New Mexico Cancer Alliance: Compassionate Use of Alpelisib","url":"https://clinicaltrials.gov/ProvidedDocs/82/NCT03941782/Prot_000.pdf","parent_key":"BE0002793"}
{"ref-id":"L6655","title":"New Mexico Cancer Alliance: Compassionate Use of Alpelisib","url":"https://clinicaltrials.gov/ProvidedDocs/82/NCT03941782/Prot_000.pdf","parent_key":"BE0002887"}
{"ref-id":"L6655","title":"New Mexico Cancer Alliance: Compassionate Use of Alpelisib","url":"https://clinicaltrials.gov/ProvidedDocs/82/NCT03941782/Prot_000.pdf","parent_key":"BE0003536"}
{"ref-id":"L4835","title":"Clinical trials","url":"https://clinicaltrials.gov/ct2/show/NCT02456883","parent_key":"BE0002638"}
{"ref-id":"L8534","title":"Polotuzumab FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L1028","title":"FDA Reports","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf","parent_key":"BE0002887"}
{"ref-id":"L1028","title":"FDA Reports","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf","parent_key":"BE0002638"}
{"ref-id":"L2315","title":"Mictoryl monograph","url":"https://www.duchesnay.com/files/pdf/mictoryl-monograph.pdf","parent_key":"BE0002638"}
{"ref-id":"L12729","title":"FDA Approved Drug Products: Pifeltro (doravirine) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210806s003lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L12729","title":"FDA Approved Drug Products: Pifeltro (doravirine) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210806s003lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L4551","title":"Eravacycline","url":"https://www.drugs.com/ppa/eravacycline.html","parent_key":"BE0002638"}
{"ref-id":"L2920","title":"Rucaparib - Drug Summary Prescribers Digital Reference","url":"http://www.pdr.net/drug-summary/Rubraca-rucaparib-23992","parent_key":"BE0002433"}
{"ref-id":"L2920","title":"Rucaparib - Drug Summary Prescribers Digital Reference","url":"http://www.pdr.net/drug-summary/Rubraca-rucaparib-23992","parent_key":"BE0002638"}
{"ref-id":"L344","title":"Daily med.","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6d46c03-bb1d-417b-b8e5-3bffe352fe29","parent_key":"BE0002793"}
{"ref-id":"L4652","title":"EMA Reports","url":"https://www.ema.europa.eu/documents/product-information/rubraca-epar-product-information_en.pdf","parent_key":"BE0002793"}
{"ref-id":"L4653","title":"Rubraca","url":"https://www.rubracahcp.com/","parent_key":"BE0002793"}
{"ref-id":"L11971","title":"FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11971","title":"FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L12075","title":"Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report","url":"https://www.pmda.go.jp/files/000210319.pdf","parent_key":"BE0003533"}
{"ref-id":"L8090","title":"FDA Approved Drug Products: Fedratinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L8090","title":"FDA Approved Drug Products: Fedratinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L8090","title":"FDA Approved Drug Products: Fedratinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf","parent_key":"BE0003606"}
{"ref-id":"L8090","title":"FDA Approved Drug Products: Fedratinib Oral Capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L7538","title":"Interactions of the H1 antihistamines","url":"http://www.jiaci.org/issues/vol16s1/5.pdf","parent_key":"BE0002363"}
{"ref-id":"L12582","title":"FDA Approved Products: Zeposia (Ozanimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L12582","title":"FDA Approved Products: Zeposia (Ozanimod) oral capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L14327","title":"FDA Approved Drug Products: Zepzelca (lurbinectedin) for intravenous injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L9013","title":"FDA Approved Drugs: Aklief\u001a","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L9013","title":"FDA Approved Drugs: Aklief\u001a","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L9013","title":"FDA Approved Drugs: Aklief\u001a","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L9013","title":"FDA Approved Drugs: Aklief\u001a","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L8093","title":"Xenleta FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11476","title":"FDA Approved Drug Products: Tazverik Tazemetostat Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf","parent_key":"BE0004866"}
{"ref-id":"L10872","title":"FDA Approved Drug Products: NUBEQA (darolutamide) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10872","title":"FDA Approved Drug Products: NUBEQA (darolutamide) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf","parent_key":"BE0003538"}
{"ref-id":"L8426","title":"DEPO-MEDROL\u001a (methylprednisolone acetate injectable suspension USP) - Product Monograph","url":"https://www.pfizer.ca/sites/default/files/201805/DEPO-MEDROL_PM_E_213592_3May2018.pdf","parent_key":"BE0002638"}
{"ref-id":"L7883","title":"FDA Approved Drug Products: Turaliotm (pexidartinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L7883","title":"FDA Approved Drug Products: Turaliotm (pexidartinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L7883","title":"FDA Approved Drug Products: Turaliotm (pexidartinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L10836","title":"FDA Approved Drug Products: Padcev (enfortumab vedotin-ejfv) for IV injection","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L571","title":"UniProt","url":"http://www.uniprot.org/uniprot/P08684","parent_key":"BE0002638"}
{"ref-id":"L572","title":"ChEMBL","url":"https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1002","parent_key":"BE0002638"}
{"ref-id":"L524","title":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/target/results/keyword","parent_key":"BE0002363"}
{"ref-id":"L573","title":"KEGG","url":"http://www.kegg.jp/dbget-bin/www_bget?dr:D08124","parent_key":"BE0002363"}
{"ref-id":"L3857","title":"NCI/NIH","url":"https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C80268&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null","parent_key":"BE0002638"}
{"ref-id":"L3842","title":"NCI/NIH","url":"https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C61767&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null","parent_key":"BE0002638"}
{"ref-id":"L10259","title":"FDA Approved Drug Products: Mavyrettm (glecaprevir and pibrentasvir) tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209394s000lbl.pdf","parent_key":"BE0004866"}
{"ref-id":"L10250","title":"Glecaprevir FDA label","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209394s006lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L1149","title":"EMA: Eurartesim Assessment Report","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf","parent_key":"BE0002638"}
{"ref-id":"L1149","title":"EMA: Eurartesim Assessment Report","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf","parent_key":"BE0002793"}
{"ref-id":"L1149","title":"EMA: Eurartesim Assessment Report","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf","parent_key":"BE0003549"}
{"ref-id":"L1149","title":"EMA: Eurartesim Assessment Report","url":"http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf","parent_key":"BE0003533"}
{"ref-id":"L2310","title":"Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa)","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1142198/","parent_key":"BE0002638"}
{"ref-id":"L2311","title":"Cytochrome P450 enzyme mediated herbal drug interactions (Part 2)","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464477/","parent_key":"BE0002433"}
{"ref-id":"L2311","title":"Cytochrome P450 enzyme mediated herbal drug interactions (Part 2)","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464477/","parent_key":"BE0002793"}
{"ref-id":"L2311","title":"Cytochrome P450 enzyme mediated herbal drug interactions (Part 2)","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464477/","parent_key":"BE0002363"}
{"ref-id":"L8582","title":"Sativex monograph","url":"https://www.bayer.ca/omr/online/sativex-pm-en.pdf","parent_key":"BE0002363"}
{"ref-id":"L2631","title":"Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO\u001a (fosnetupitant/palonosetron) in the United States","url":"https://www.helsinn.com/news-and-events/helsinn-group-announces-the-fda-approval-of-the-iv-formulation-of-akynzeo-fosnetupitant-palonosetron-in-the-united-states/","parent_key":"BE0002638"}
{"ref-id":"L4565","title":"APTIOM \u001a (eslicarbazepine acetate","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11994","title":"FDA Approved Drug Products: Celestone Soluspan (betamethasone sodium phosphate and betamethasone acetate) injectable suspension","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/014602s062lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L13239","title":"FDA: Fact Sheet For Health Care Providers EUA of Remdesivir","url":"https://www.fda.gov/media/137566/download","parent_key":"BE0002887"}
{"ref-id":"L13239","title":"FDA: Fact Sheet For Health Care Providers EUA of Remdesivir","url":"https://www.fda.gov/media/137566/download","parent_key":"BE0002363"}
{"ref-id":"L13239","title":"FDA: Fact Sheet For Health Care Providers EUA of Remdesivir","url":"https://www.fda.gov/media/137566/download","parent_key":"BE0002638"}
{"ref-id":"L13769","title":"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L13769","title":"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L13769","title":"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L13769","title":"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf","parent_key":"BE0003533"}
{"ref-id":"L10842","title":"FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10397","title":"FDA Approved Drug Products: Oxbrytatm (voxelotor) tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10397","title":"FDA Approved Drug Products: Oxbrytatm (voxelotor) tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L10397","title":"FDA Approved Drug Products: Oxbrytatm (voxelotor) tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L10397","title":"FDA Approved Drug Products: Oxbrytatm (voxelotor) tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L10163","title":"FDA Approved Drug Products: Brukinsa (zanubrutinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10163","title":"FDA Approved Drug Products: Brukinsa (zanubrutinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L10163","title":"FDA Approved Drug Products: Brukinsa (zanubrutinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf","parent_key":"BE0004866"}
{"ref-id":"L10896","title":"FDA Approved Drug Products: Rinvoq (upadacitinib) extended-release tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10896","title":"FDA Approved Drug Products: Rinvoq (upadacitinib) extended-release tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L13050","title":"FDA Approved Drug Products: PEMAZYRE (pemigatinib) tablets, for oral use","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11136","title":"FDA Approved Drug Products: Avapritinib Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L11136","title":"FDA Approved Drug Products: Avapritinib Oral Tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L10926","title":"FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0002362"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0002433"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0003549"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0002793"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0003536"}
{"ref-id":"L9395","title":"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf","parent_key":"BE0002363"}
{"ref-id":"L13604","title":"FDA Approved Drug Products: Retevmo (selpercatinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf","parent_key":"BE0002638"}
{"ref-id":"L13604","title":"FDA Approved Drug Products: Retevmo (selpercatinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf","parent_key":"BE0002887"}
{"ref-id":"L13604","title":"FDA Approved Drug Products: Retevmo (selpercatinib) capsules","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf","parent_key":"BE0004866"}